ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 53 filers reported holding ALIGOS THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $17,124 | -39.6% | 22,924 | -21.4% | 0.00% | – |
Q2 2023 | $28,337 | -43.0% | 29,183 | -48.7% | 0.00% | – |
Q1 2023 | $49,693 | -42.3% | 56,857 | -37.1% | 0.00% | – |
Q4 2022 | $86,159 | -37.1% | 90,418 | -27.3% | 0.00% | – |
Q3 2022 | $137,000 | -41.9% | 124,426 | -36.3% | 0.00% | -100.0% |
Q2 2022 | $236,000 | -45.9% | 195,412 | -3.6% | 0.00% | 0.0% |
Q1 2022 | $436,000 | -45.5% | 202,692 | +200.9% | 0.00% | -50.0% |
Q4 2021 | $800,000 | -42.6% | 67,369 | -25.0% | 0.00% | -33.3% |
Q3 2021 | $1,394,000 | – | 89,863 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 2,320,381 | $1,733,325 | 0.92% |
TANG CAPITAL MANAGEMENT LLC | 3,329,048 | $2,486,799 | 0.35% |
Vivo Capital, LLC | 3,547,030 | $2,649,631 | 0.29% |
Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $555,182 | 0.22% |
Newtyn Management, LLC | 920,000 | $687,240 | 0.17% |
SILVERARC CAPITAL MANAGEMENT, LLC | 631,887 | $472,020 | 0.14% |
EcoR1 Capital, LLC | 3,948,360 | $2,949,425 | 0.10% |
HHLR ADVISORS, LTD. | 2,309,764 | $1,725,394 | 0.04% |
Baker Brothers Advisors | 2,076,400 | $1,551,071 | 0.01% |
HARBOURVEST PARTNERS LLC | 18,783 | $14,031 | 0.01% |